Warther Private Wealth LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Warther Private Wealth LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,664 shares of the biopharmaceutical company’s stock, valued at approximately $3,322,000. Regeneron Pharmaceuticals makes up 1.1% of Warther Private Wealth LLC’s holdings, making the stock its 21st largest holding.

Several other institutional investors have also modified their holdings of the company. CWM LLC boosted its position in shares of Regeneron Pharmaceuticals by 1.1% during the 3rd quarter. CWM LLC now owns 2,272 shares of the biopharmaceutical company’s stock valued at $2,389,000 after purchasing an additional 25 shares in the last quarter. Ritholtz Wealth Management lifted its stake in Regeneron Pharmaceuticals by 17.6% during the third quarter. Ritholtz Wealth Management now owns 729 shares of the biopharmaceutical company’s stock valued at $766,000 after purchasing an additional 109 shares during the last quarter. Creative Planning boosted its holdings in Regeneron Pharmaceuticals by 22.7% during the third quarter. Creative Planning now owns 11,793 shares of the biopharmaceutical company’s stock worth $12,397,000 after buying an additional 2,178 shares in the last quarter. Swedbank AB grew its position in Regeneron Pharmaceuticals by 10.1% in the third quarter. Swedbank AB now owns 149,363 shares of the biopharmaceutical company’s stock worth $157,016,000 after buying an additional 13,705 shares during the last quarter. Finally, Magnus Financial Group LLC increased its holdings in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. Magnus Financial Group LLC now owns 1,588 shares of the biopharmaceutical company’s stock valued at $1,669,000 after buying an additional 20 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of recent research reports. Royal Bank of Canada cut their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Citigroup cut their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Robert W. Baird decreased their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. Finally, Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Down 3.6 %

REGN stock opened at $665.46 on Wednesday. The firm has a market cap of $73.13 billion, a PE ratio of 17.38, a PEG ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a fifty day simple moving average of $714.37 and a 200 day simple moving average of $906.38. The company has a current ratio of 4.73, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $11.86 earnings per share. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.53%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.